Euronext Paris · Healthcare
Invest in Nicox stock from India
Indian and foreign residents can buy Nicox (ALCOX) shares directly through Paasa.
By Paasa · Updated
Nicox at a glance
- Price
- €0.33-€0.01 (1.76%)
- Market cap
- €32.47M
- Day range
- €0.33 – €0.34
- P/E
- -7.28
- Dividend yield
- None
- Volume
- 196.03K
- 1 month
- -13.25%
- 6 months
- -14.58%
- YTD
- +12.08%
- 1 year
- -7.09%
- 5 years
- -89.40%
Nicox statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | €16.8M | €7.9M | €6.9M | €3.3M | €7.2M |
| Gross profit | €6.5M | €6.7M | −€11.5M | −€14.7M | −€10.7M |
| Operating income | −€13.6M | −€9.9M | −€17.1M | −€34.1M | −€46.0M |
| Net income | −€2.4M | −€22.4M | −€20.9M | −€31.3M | −€43.8M |
| Earnings per share | −€0.03 | −€0.35 | −€0.42 | −€0.62 | −€1.17 |
| EBITDA | €18.9M | −€20.6M | −€19.7M | −€21.4M | −€16.0M |
| Total assets | €10.4M | €24.4M | €53.0M | €93.2M | €114.6M |
| Total debt | €406.3K | €17.7M | €25.2M | €26.5M | €21.5M |
| Cash and short-term investments | €4.1M | €10.5M | €11.3M | €27.1M | €42.0M |
| Shareholders' equity | €6.0M | €3.4M | €21.4M | €42.3M | €75.6M |
| Operating cash flow | €0.0 | €0.0 | €0.0 | −€23.1M | −€18.5M |
| Free cash flow | €0.0 | €0.0 | €0.0 | −€23.2M | −€18.5M |
| Capital expenditure | €0.0 | €0.0 | €0.0 | −€42.0K | −€8.0K |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in EUR; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Valerio Therapeutics | ALVIO.PA | €0.53 | €265.21M |
| Theraclion | ALTHE.PA | €0.69 | €50.74M |
| Novacyt | ALNOV.PA | €0.50 | €35.89M |
| genOway | ALGEN.PA | €2.34 | €28.88M |
| Valbiotis | ALVAL.PA | €0.69 | €24.49M |
| Diagnostic Medical Systems | ALDMS.PA | €0.91 | €23.50M |
| GenSight Biologics | SIGHT.PA | €0.10 | €16.20M |
| Aelis Farma | AELIS.PA | €0.90 | €12.27M |
Peers as grouped by the data provider. This is not an investment recommendation.
How to invest in Nicox from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to EUR when you buy.
Step 3
Search ALCOX and buy
Find Nicox by name or by its ticker, ALCOX, and place your order.
Why invest in Nicox from India
What Nicox does
Nicox S.A. is an ophthalmology firm operating both within France and internationally, dedicated to developing treatments that preserve sight and enhance eye health. Its most advanced investigational therapy, NCX 470, is a unique nitric oxide-donating bimatoprost eye drop currently undergoing Phase 3 clinical trials, designed to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox operates in the Biotechnology industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy Nicox stock from India?
Yes. Indian residents and NRIs can buy Nicox (ALCOX) shares directly through Paasa. Nicox is listed on Euronext Paris, in the Biotechnology industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
What tax do I pay in India when I sell Nicox shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the EUR/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.